Behcet's disease: Immunogenetic studies and therapeutic update;La maladie de behcet: Facteurs genetiques, aspects immunologiques et nouveautes therapeutiques

Presse Medicale

Volumn 28, Issue 20, 1999, Pages 1080-1084

  Tohme, A ^a   El Khoury, I ^a   Ghayad, E ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PENTOXIFYLLINE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR; CORTICOSTEROID;

BEHCET DISEASE; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE MARKER; GENETIC SUSCEPTIBILITY; HLA SYSTEM; HUMAN; IMMUNOGENETICS; PATHOGENESIS; REVIEW; T LYMPHOCYTE SUBPOPULATION; TREATMENT PLANNING; GENETICS; IMMUNOLOGY;

ADRENAL CORTEX HORMONES; BEHCET SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0033526657     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Hamza M. Pathologie et physiopathologie de la maladie de Behçet. Rev Rhum (Ed. Fr.) 1988 ; 55:771-8.
2. The Behçet Disease Research Committee of Japan. Behçet's disease: Guide to diagnosis of Behçet's disease. Jpn J Ophatalmol 1974 ; 18:291-4.
3. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990 ; 335:1078-80.
4. Fodil N, Laloux L, Wanner V et al. Allelic repertoire of the human MHC class I MICA gene. Immunogenetics 1996 ; 44:351-7.
5. Mizuki N, Ohno S. Immunogénétique de la maladie de Behçet. Rev Rhum (Ed Fr) 1996 ; 63:607-14 .
6. Hasan A, Fortune F, Wilson A et al. Role of Tcells in pathogenesis and diagnosis of Behçet's disease. Lancet 1996 ; 347:789-94.
7. Ghayad E, Tohmé A. La maladie de Behçet au Liban. Ed Librairie du Liban, 1995.
8. Ohno S, Aoki K, Sugiura S, Nakayama E, Itakura K, Aizawa M. HLAB5 and Behçet's disease. Lancet 1973 ; 2:1383-4.
9. Mizuki N, Inoko H, Ando H et al. Behçet's disease associated with one of the HLA-B51 subantigens, HLA B 5101 .Am J Ophtalmol 1993 ; 116:406-9.
10. Messini H, Spyropoulo M, Papadimitropoulos M et al. HLA-B5 (51) genomic analysis in Greek patients with adamantiades-Behçet's disease (A-BD): Correlation with certain disease characteristics. In: VII th International conference on Behçet's Disease (Absbract A34). Rev Rhum (Ed Anglaise), 1996 ; 63:534.
11. Roux H, Fresko I. La maladie de Behçet en quête de son étiologie. Rev Rhum (Ed.fr) 1995 ; 62:357-60.
12. Mineshita S, Wan L, Ding S et al. Distribution of HLA classe I, II antigens of chinese and japanese patients of Behçet's disease. Rev Med Interne 1993; 14(suppl. 1), 033.
13. Mizuki N, Ota M, Kimura M et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: A strong association of six GCT repetitions with Behçet disease. Genetics. Proc Natl Acad Sci USA 1997 ; 94:1298-303.
14. Kaklamani V, Valopoulos G, Kaklamani P. Behçet's disease Semin arthritis Rheum 1998 ; 27:197-217.
15. Bang D, Cho YH, Cho HJ, Lee S, Sohn S, Lee ES. Detection of herpes simplex virus DNA by polymerase chain reaction in genital ulcer of patients with behçet's disease. In: VIIth International conference on Behçet's disease (Abstract A19), Rev Rhum (Ed Anglaise), 1996:63:532.
16. Cantini F, Emmi L, Niccoli L, Padula A, Salvarani C, Olivieri I. Lack of association beween chronic hepatitis C virus infection and Behçet's disease. Clin Exp Rheumatol 1997 ; 15:338-9.
17. Kiraz S, Ertenli I, Benekli M, Calguneri M, Parvovirus B19 infection in Behçet's disease. Clin Exp Rheumatol 1996 ; 14:71-3.
18. Mege JL, Dilsen N, Sanguedolce V et al. Overproduction of monocyte derived tumor necrosis factor, interleukin 6, IL8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial mediterranean fever and healthy controls. J Rheumatol 1993 ; 20:1544-9.
19. Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann Rheum Dis 1996 ; 55:128-33.
20. Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoglu T. Monocyte activity in Behçet's disease. Br J Rheumatol 1996 ; 35:424-9.
21. Pronai L, Ichikawa Y, Nakazawa H, Arimori S. Enhanced superoxide generation and the decreased superoxide scavenging activity of peripheral blood leucocytes in Behçet's disease. Effects of Colchicine. Clin Exp Rheumatol 1991 ; 9:227-33.
22. Yamashita N, Kaneaoka H, Kaneko S et al. Role of gammadelta T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997 ; 107:241-7.
23. Hasan A, Fortune F, Wilson A, Lehner T. Role of T cells in Behçet's disease (Author's reply). Lancet 1996 ; 347:1631-2.
24. Eksioglu-Demiralp E, Direskeneli H, Sahin H et al. Increased CD4+ CD16+, CD4+ CD56+ and CD8+ CD11B+ T lymphocytes in Behçet's disease. In: VII th international conference on Behçet's disease (Abstract AO7). Rev Rhum (Ed anglaise) 1996 ; 63:530.
25. Kahan A, Hamzaoui K, Ayed K. Abnormalities of T lymphocyte subsets in Behçet's disease demontrated with anti-CD45RA and anti-CD29 monoclonal antibodies. J Rheumatol 1992 ; 19:742-6.
26. Sayinalp N, Oezcebe OI, Oezdemir O, Haznedaroglu I, Dundar S, Kirazli S: Cytokines in Behçet's disease. J Rheumatol 1996 ; 23:321-2.
27. Sakane T, Suzuki N, Ueda Y: Analysis of interleukin -2 activity in patients with Behçet's disease. Arthritis Rheum 1986 ; 29:371-8.
28. Turan B, Gallati H, Erdi H, Gurler A, Michel B, Villiger P. Systemic levels of the T cell regulatory cytokines IL 10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997 ; 24:128-32.
29. Itoh R, Takenaka T, Okitsu Negishi S, Matsushima K, Mizoguchi M. Interleukin 8 in Behçet's disease. J Dermatol 1994 ; 21:397-404.
30. Hull RG, Harris EN, Gharavi AE et al. Anticardiolipin antibodies:Occurrence in Behçet's syndrome. Ann Rheum Dis 1984 ; 43:746-8.
31. Vaiopoulos G, Hatzinicolaou P, Tsiroyanni A et al. Antineutrophil cytoplasmic antibodies in Adamantiades-Behçet's disease. Br J Rheumatol 1994 ; 33:406-7.
32. Yazigi H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behçet's syndrome. Drugs 1991 ; 42:796-804.
33. Cochereau-Massin I, Wechsler B, Le Hoang P et al. Prognosis of uveitis in french patients. In: O'Duffy JD, Kokmen E. Behçet's disease. Basic and clinical aspects. Mayo clinic, Rochester, Minnesota, 1991, 85-92.
34. Ghayad E, Tohmé A. La maladie de Behçet au Liban. Rev Rhum (ed fr) ; 1994 ; 60:287-8.
35. Davatchi F, Baygan F, Chams H, Chams C. Cyclophosphamide in the treatment of the ocular manifestations of Behçet's disease. J Rheumatol 1984 ; 11:404-5.
36. Le Thi Huong D, Fain O, Wechsler B et al. Intérêt des «bolus» de cyclophosphamide dans la maladie de Behçet. Expérience de 17 cas. Presse Med 1990 ; 19:1355-8.
37. Hamuryudan V, Ozyazgan Y, Hizli N et al. Azathioprine in Behçet's syndrome. Effects on long-term prognosis. Arthritis Rheum 1997 ; 40:769-74.
38. Graham E, Binder A, Denman AM, Dinning WJ, Sanders MD. Cyclosporin A in the treatment of severe Behçet's uveitis. In: Lehner T, Barnes CG. Recent advances in Behçet's disease. London. Royal society of Medicine, services, 1986.
39. Ozyazgan Y, Yurdakul S, Yazici H et al. Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophtalmol 1992 ; 76:241-3.
40. Masuda K, Urayama A, Kogure M, Nakajima A, Nakae K, Inaba G. Double -masked trial of cyclosporin versus colchicine and long term open study of cyclosporin in Behçet's disease. Lancet 1989 ; 1:1093-6.
41. Lim K, Daniel Su WP, Schroeter A, Sabers C, Abraham R, Pittelkow M. Cyclosporine in the treatment of dermatologic disease: An update. Mayo clin Proc 1996 ; 71:1182-91.
42. Barnes CG. Behçet's syndrome. Topical Reviews 1991 ; No. 18.
43. Suzuki N, Kaneko S, Ichino M, Mihara S, Wakisaka S, Sakane T. In vivo mechanisms for the inhibition of T lymphocyte activation by long term therapy with tacrolimus (FK-506). Experience in patients with Behçet's disease. Arthritis Rheum 1997 ; 40:1157-67.
44. Palestine AG, Nussesblatt RB, Gelatio M. Therapy for human auto-immune uveitis with low-dose cyclosporin plus bromocryptine. Transpl Proc 1988 ; 20(suppl. 4):131-5.
45. Schumacher HR Jr, ed. Primer on Rheumatic Diseases. 10th ed. Atlanta. Arthritis Foundation 1993:206-7.
46. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med 1996 ; 124:891-3.
47. Bick RL, Baker WF. The antiphospholipid and thrombosis syndromes. Med Clin North Am 1994 ; 78:667-84.
48. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with behçet's disease. A randomized clinical trial. Arthritis Rheum 1996 ; 39:2062-5.
49. Hamuryudan V, Moral F, Yurdakul S et al. Systemic interferon 2 B treatment in Behçet's syndrome. J Rheumatol 1994 ; 21:1098-100.
50. Dundar S, Demiroglu H, Ozcebe O, Ozdemir O, Caliskan S, Eldem B. Alpha interferon in Behçet's disease. Hematol Rev 1996 ; 9:285-90.
51. Segawa F, Shimizu Y, Saito E, Kinoshita M. Behçet's disease induced by interferon therapy for chronic myelogenous leukemia. J Rheumatol 1995 ; 22:1183-4.